Phase 2 Parkinson's Disease Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People between 30 and 80 years of age at the time of screening.
• People who have been diagnosed with Parkinson's disease, confirmed using standard medical criteria, including slowness of movement and symptoms that affect one side of the body more than the other.
• People with mild to moderate Parkinson's disease, rated at stage 3 or lower on a standard Parkinson's scale (Hoehn and Yahr) during periods when their medication is working well.
• People who experience an average of at least 3 hours per day of "OFF" time (periods when Parkinson's symptoms are not well controlled), based on home symptom diaries, with at least 2.5 hours of OFF time each day during the lead-up period before the trial begins.
• People who score 24 or higher on a standard memory and thinking assessment called the Montreal Cognitive Assessment (MoCA) at screening.
• People who are able to walk independently, with or without a walking aid.
• People who are able to swallow tablets or capsules.
• People whose Parkinson's medications have remained unchanged for at least 4 weeks before screening — or at least 12 weeks for a specific type of medication called MAO-B inhibitors.
• People who are taking levodopa at least four times daily (in standard or controlled-release forms), or at least three times daily if using an extended-release formulation such as Rytary or Crexont.

Who may not be able to join:

• People whose condition is a form of parkinsonism other than typical Parkinson's disease, such as secondary or atypical parkinsonism.
• People who have previously received, or who are expected to receive during the trial, advanced Parkinson's treatments such as continuous medication delivery systems or Parkinson's-related brain surgery.
• People who experience involuntary movements (dyskinesias) severe enough that, in the study doctor's opinion, these would interfere with taking part in the trial.
• People whose involuntary movements are only of certain specific types (such as those occurring in the OFF state, diphasic, myoclonic, or dystonic dyskinesias), without the more typical peak-dose type of involuntary movements.
• People who are currently taking medications that block dopamine, with the exception of low-dose quetiapine (up to 50 mg per day) taken for sleep problems.
• People who regularly use on-demand "rescue" Parkinson's medications more than three times per week.

Important: Always verify eligibility with the trial site directly before applying.